NAS:EOLS (USA) Also trade in: Germany UK

Evolus Inc

$ 19 -0.87 (-4.38%)
Volume: 903,283 Avg Vol (1m): 839,406
Market Cap $: 520.09 Mil Enterprise Value $: 476.11 Mil
P/E (TTM): 0.00 P/B: 6.91
Earnings Power Value 0
Net Current Asset Value -0.24
Tangible Book -0.17
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5.3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.49
Cash-To-Debt range over the past 10 years
Min: 1.49, Med: 3.07, Max: 6.26
Current: 1.49
1.49
6.26
Debt-to-Equity 1.19
Debt-to-Equity range over the past 10 years
Min: -8.41, Med: 0.2, Max: 3.85
Current: 1.19
-8.41
3.85
Debt-to-EBITDA -1.38
Debt-to-EBITDA range over the past 10 years
Min: -18.36, Med: -2.28, Max: -0.37
Current: -1.38
-18.36
-0.37
Altman Z-Score 0.54
DISTRESS
GREY
SAFE

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -74.98
ROE range over the past 10 years
Min: -1060.22, Med: -819.65, Max: -74.98
Current: -74.98
-1060.22
-74.98
ROA % -31.30
ROA range over the past 10 years
Min: -38.27, Med: -27.1, Max: -3.9
Current: -31.3
-38.27
-3.9
ROC (Joel Greenblatt) % -5472833.33
ROC (Joel Greenblatt) range over the past 10 years
Min: -5472833.33, Med: -1702.16, Max: -1487.28
Current: -5472833.33
-5472833.33
-1487.28
3-Year Total EBITDA Growth Rate -14.50
N/A
3-Year EPS w/o NRI Growth Rate -0.70
N/A

» EOLS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:EOLS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325411    SIC : 2833
Compare NAS:CPRX OCSE:VELO NAS:NEOS XCNQ:ISOL XKRX:002250 XKLS:7081 TSE:4594 XKRX:011040 TSXV:THCX NAS:TOCA XCNQ:LHS NZSE:CVT TSE:4597 DHA:ACI XKRX:000020 IST:DEVA TSE:4538 TSXV:FIRE XKRX:023910 NAS:SLDB
Traded in other countries EVL.Germany 0K16.UK
Address 17901 Von Karman Avenue, Suite 150, Irvine, CA, USA, 92614
Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

Ratios

Current vs industry vs history
PB Ratio 6.91
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 17.89
Current: 6.91
0
17.89
EV-to-EBIT -7.31
EV-to-EBIT range over the past 10 years
Min: -93.18, Med: 0, Max: 0
Current: -7.31
-93.18
0
EV-to-EBITDA -7.40
EV-to-EBITDA range over the past 10 years
Min: -94.65, Med: 0, Max: 0
Current: -7.4
-94.65
0
Current Ratio 14.80
Current Ratio range over the past 10 years
Min: 0.01, Med: 12.96, Max: 19.43
Current: 14.8
0.01
19.43
Quick Ratio 14.52
Quick Ratio range over the past 10 years
Min: 0.01, Med: 12.96, Max: 19.43
Current: 14.52
0.01
19.43

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -13.90
N/A

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -13.82
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.44, Med: 0, Max: 0
Current: -13.82
-21.44
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N